Loading stock data…
MBX
$29.87+0.87 (+3.00%)
After Hours$29.29-0.58 (-1.94%)· Last close Jun 9
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MBX Biosciences, Inc. in the Healthcare sector is trading at $29.87. Wall Street consensus targets $69.09 (11 analysts), implying a +131.3% move over the next 12 months. The stock is currently 35% below its 52-week high of $45.85, remaining 7.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +131.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$29.87
Potential Downside
0%
Whystock Fair Value$29.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$69.09+131.3%
Range$20.00 – $91.00
Fundamentals
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109),...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-19.78%
Volume
Today's trading volume
296,000
Recent News
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.
Insider Stock Buying Reaches US$1.06m On MBX Biosciences
Multiple insiders secured a larger position in MBX Biosciences, Inc. ( NASDAQ:MBX ) shares over the last 12 months...
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development milestones across its endocrine and metabolic disease pipeline. President and CEO Kent Hawr
3 Overlooked Stocks Set to Soar in 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase
MBX Biosciences targets endocrine and metabolic disorders with novel peptide therapies, advancing candidates across several clinical phases.